June 29, 2020 / 4:20 PM / 12 days ago

Roche's combo therapy for advanced breast cancer gets U.S. FDA approval

June 29 (Reuters) - The U.S. Food and Drug Administration on Monday approved Roche Holding AG's combination therapy for a form of advanced breast cancer that has spread to other parts of the body.

The therapy, Phesgo, was approved for patients with HER2-positive breast cancer and comes with a boxed warning flagging risks of potential heart failure, fetal harm and lung toxicity. (bit.ly/3idY5VW) (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below